
|Articles|January 31, 2022
Daily Medication Pearl: Mesalamine (Apriso)
Author(s)Saro Arakelians, PharmD
Mesalamine (Apriso) is a locally acting aminosalicylate indicated to treat and prevent flare-ups of ulcerative colitis.
Advertisement
Medication Pearl of the Day: Mesalamine (Apriso)
Indication: Mesalamine (Apriso) is a locally acting aminosalicylate indicated for the maintenance of diarrhea, upper abdominal pain, nausea, nasopharyngitis, flu or flu-like remission of ulcerative colitis in adults.
Insight:
- Dosing: Four capsules once daily (1.5 g/day) in the morning with or without food. Do not co-administer with antacids.
- Dosage forms: Extended-release capsules 0.375 g.
- Adverse events: The most common adverse reactions (incidence ≥3%) are headache, diarrhea, upper abdominal pain, nausea, nasopharyngitis, flu or flu-like remission of ulcerative colitis in adults, illness, and sinusitis.
- Mechanism of action: The mechanism of action of mesalamine is unknown but appears to be local to the intestinal mucosa rather than systemic.
- Manufacturer: Catalent Pharma
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
3
Biosimilar Stivant Shows Noninferior Efficacy and Comparable Safety to Reference Bevacizumab
4
Current and Emerging BCMAxCD3 Bispecifics
5